Hydroxychloroquine Market Synopsis:
Hydroxychloroquine Market Size Was Valued at USD 4.22 Billion in 2023, and is Projected to Reach USD 6.89 Billion by 2032, Growing at a CAGR of 5.6% From 2024-2032.
Hydroxychloroquine is a drug that is actively used to combat malaria; in the treatment of rheumatoid arthritis, lupus, certain diseases of the autoimmune system. It is also prescribed to treat and prevent other conditions which include COVID-19. Offered both as a tablet and a solution for intramuscular administration, hydroxychloroquine has been recently introduced as possessing immunomodulatory effects and being used in the treatment of viral and other infections.
The market for hydroxychloroquine is determined by the growing incidence of the autoimmune diseases including rheumatoid arthritis and lupus, malaria and some viral infections like COVID-19. Hydroxychloroquine had some popularity during the COVID-19 pandemic because it was first used as an antimalarial and then discovered to help with autoimmune diseases given its immunomodulatory and anti-inflammatory effects. In the recent years, the medication has been under research and practice in entrance in different ways, especially as a treatment during the Covid -19 pandemic discovered to have more attention. Shrouded in early concerns around its effectiveness against Covid-19, hydroxychloroquine is still a core medicine for some autoimmune disorders, adding to the substance’s market importance.
The hydroxychloroquine market around the globe is expanding with rising research and development focus on enhancing its formulation techniques and the identification of more applications. The market is also notable for its responsiveness to a shifting regulatory framework visible in approvals and guidelines handed out by the FDA or EMA. Despite these compliance challenges such as safety, adverse effects, hydroxychloroquine’s efficacy established for several diseases would further support its market stand. Variation of market demand by geography due to local disease risks and access to healthcare further contribute to a similar effect. Investment in rheumatic diseases is expected to gain momentum primarily in the emerging market especially in countries with high malaria rates in the developing world, while in the developed world the demand for these drugs is expected to remain constant due to ongoing rheumatoid arthritis and lupus.
Hydroxychloroquine Market Trend Analysis:
Use of Hydroxychloroquine in Autoimmune Diseases
-
A huge market share based on its usage in auto immune diseases such as rheumatoid arthritis and lupus has been evident in defining the general trend. This therapeutic application is increasing the market size of hydroxychloroquine in both mature and emerging markets, though autoimmune diseases are increasing in incidence globally as a result of changes in diet, genetics, and even the environment. Both rheumatoid arthritis and lupus are chronic diseases that are treated with hydroxychloroquine, which should also result in steady sales in therapeutic segment. Hydroxychloroquine is preferred omce again due to its effectiveness in controlling such manifestations as pain and inflammation with a relatively benign risk profile in contrast to other immunosuppressive agents.
- The use of hydroxychloroquine in autoimmune diseases is also sustained by research and clinical trials devoted to the efficacy of this drug for treatment different forms of systemic lupus erythematosus and rheumatoid arthritis. The drug is mainly used in the treatment of these disease areas and as healthcare providers affirm to its contribution to enhancement of patients’ gains, then its market position within these disease areas will expand. Newer researches and changing methods of treatment for autoimmune diseases may improve its demand in the global market in the future.
Expanding Use in Infectious Diseases
-
Traditionally a malaria treatment drug, this is an opportunity to try the drug on other infectious diseases especially a country endemic in tropical diseases. With a resurgence of diseases like malaria and the global battle against new emerge notifiable diseases could present a new market for hydroxychloroquine on another front. Since malaria persists in many developing countries especially in sub-Saharan Africa, use of hydroxychloroquine as first-line antimalarial drug also contributes towards moderate market growth for this drug. Furthermore, as far as the potential of hydroxychloroquine in the treatment of other VIRAL infections for example, dengue, zika and so on makes new markets available for exploration.
- Despite the emerging problems associated with the use of hydroxychloroquine for emerging viral diseases, it remains a prospect diamonds that broadens the pharmaceutical company’s indications and growth in global markets. Efforts aimed at mobilizing governments and healthcare organizations to help eradicate infectious diseases in underprivileged areas can also cause people to require hydroxychloroquine. They may include extending the use of the drug in the disease management programmes, increasing its accessibility, and even increasing the accessibility in the low income countries. The creation of new drugs formulations and ways of their administration can increasingly enhance this opportunity on the benefit not only on the world health, but also at the market of hydroxychloroquine.
Hydroxychloroquine Market Segment Analysis:
Hydroxychloroquine Market is Segmented on the basis of Formulation, Distribution Channel, Application, End User, and Region
By Type, Tablets segment is expected to dominate the market during the forecast period
-
The formulated tablets of hydroxychloroquine remain the most popular form of using the drug and mostly in the management of chronic diseases including rheumatoid arthritis and lupus. Tablet dosage form is easier to administer and is well appreciated by patients that need to be on medication for long term. However, due to the existence of many tablet forms, some of which are strong, it can be easily adjusted for the dosage suitable for many patients irrespective of the severity of the disease. Hydroxychloroquine tablets are also cheaper to develop cutting on production costs since they are affordable widely especially in regions with high malaria prevalence.
- Injections: As for hydroxychloroquine form release, although most market products are based on tablets, more attention is paid to the injectable form of the drug relevant to the use in the hospitals or cases when oral medications can be taken with difficulty. Parenteral hydroxychloroquine is employed in complicated malaria or illness in which the patient requires a swift therapeutic response. The advantage for this formulation is in giving accurate doses and quicker actions required for critical patients. However, the injectable form is comparatively rare and quite expensive compared to the prices of tablets while the latter is relatively widespread and cheaper than the former; thus making it more appropriate for use in health facilities and other professional facilities.
By Application, Malaria segment expected to held the largest share
-
HCQ is a key antimalarial drug of choice since the beginning of this century. Which it has proved useful in the treatment of this parasitic disease particularly in areas with high incidence of malaria such as the sub-Saharan Africa and Asia Pacific region thus making this therapeutic a standard option in th therapy of this disease. As with most malaria drugs, hydroxychloroquine affects the maturation cycle of the parasite within the human body making it very crucial for malaria treatment. The increase in malaria cases of some regions, coupled with endeavors against drug resistance, maintain hydroxychloroquine’s demand, peculiarly in tropical countries.
- Rheumatoid Arthritis, Lupus, and COVID-19: Some autoimmune diseases, which hydroxychloroquine treats include rheumatoid arthritis and lupus meaning the drug has become vital in the management of such diseases. These diseases in most cases are chronic therefore creating continuous demand for this drug. Moreover, the brief period of time that hydroxychloroquine was used to treat COVID-19 received much attention. It has controversies about the effectiveness in treating Covid-19 Though its usage in the beginning of the pandemic had a temporary effect on demand. Hydroxychloroquine demand from autoimmune diseases combined with its application in infectious diseases guarantees it a role in diverse uses in the medical field.
Hydroxychloroquine Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast period
-
North America region holds the largest market of hydroxychloroquine due to high incidence of auto immune diseases including rheumatoid arthritis and lupus. The advancement in health facility in the region complemented by research and innovation has seen most of the patient being treated using hydroxychloroquine in the management of the above conditions. The United States, in particular, is a major consumer of the drug with this faller being standard of care in several chronic illnesses. In addition, North America is equipped with the proper healthcare systems that will allow the community to have access to hydroxychloroquine even though there are constant changes in the safety profile of the drug.
- Beside the autoimmune diseases, the requirement of hydroxychloroquine in malaria treatment especially in regions which are highly affected by the disease aids North America to lead the global market. The investments that have been made by these region’s in global malaria eradication programs means that hydroxychloroquine has a permanent place in disease management strategies. Efforts have also been continued by regulatory bodies like the FDA for continuously observing and approving of hydroxychloroquine for different indications which strengthens more the position of hydroxychloroquine in the North American market.
Active Key Players in the Hydroxychloroquine Market:
-
Amgen (USA)
- Bristol-Myers Squibb (USA)
- Cipla Ltd. (India)
- GSK (GlaxoSmithKline) (UK)
- Hikma Pharmaceuticals (Jordan)
- Lupin Pharmaceuticals (India)
- Mylan N.V. (USA)
- Novartis AG (Switzerland)
- Sandoz (Novartis) (Switzerland)
- Sanofi (France)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Zydus Cadila (India)
- Other Active Players
|
Global Hydroxychloroquine Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 4.22 Billion |
|
Forecast Period 2024-32 CAGR: |
5.6% |
Market Size in 2032: |
USD 6.89 Billion |
|
Segments Covered: |
By Formulation |
|
|
|
By Application |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the Report: |
|
||
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Hydroxychloroquine Market by Application
4.1 Hydroxychloroquine Market Snapshot and Growth Engine
4.2 Hydroxychloroquine Market Overview
4.3 Malaria
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Malaria: Geographic Segmentation Analysis
4.4 Rheumatoid Arthritis
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Rheumatoid Arthritis: Geographic Segmentation Analysis
4.5 Lupus
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Lupus: Geographic Segmentation Analysis
4.6 COVID-19
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 COVID-19: Geographic Segmentation Analysis
4.7 Others
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.7.3 Key Market Trends, Growth Factors and Opportunities
4.7.4 Others: Geographic Segmentation Analysis
Chapter 5: Hydroxychloroquine Market by Distribution Channel
5.1 Hydroxychloroquine Market Snapshot and Growth Engine
5.2 Hydroxychloroquine Market Overview
5.3 Hospitals
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Hospitals: Geographic Segmentation Analysis
5.4 Pharmacies
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Pharmacies: Geographic Segmentation Analysis
5.5 Online Pharmacies
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Online Pharmacies: Geographic Segmentation Analysis
Chapter 6: Hydroxychloroquine Market by Formulation
6.1 Hydroxychloroquine Market Snapshot and Growth Engine
6.2 Hydroxychloroquine Market Overview
6.3 Tablets
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Tablets: Geographic Segmentation Analysis
6.4 Injections
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Injections: Geographic Segmentation Analysis
Chapter 7: Hydroxychloroquine Market by End-User
7.1 Hydroxychloroquine Market Snapshot and Growth Engine
7.2 Hydroxychloroquine Market Overview
7.3 Hospitals
7.3.1 Introduction and Market Overview
7.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
7.3.3 Key Market Trends, Growth Factors and Opportunities
7.3.4 Hospitals: Geographic Segmentation Analysis
7.4 Clinics
7.4.1 Introduction and Market Overview
7.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
7.4.3 Key Market Trends, Growth Factors and Opportunities
7.4.4 Clinics: Geographic Segmentation Analysis
7.5 Homecare
7.5.1 Introduction and Market Overview
7.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
7.5.3 Key Market Trends, Growth Factors and Opportunities
7.5.4 Homecare: Geographic Segmentation Analysis
Chapter 8: Company Profiles and Competitive Analysis
8.1 Competitive Landscape
8.1.1 Competitive Benchmarking
8.1.2 Hydroxychloroquine Market Share by Manufacturer (2023)
8.1.3 Industry BCG Matrix
8.1.4 Heat Map Analysis
8.1.5 Mergers and Acquisitions
8.2 SANOFI (FRANCE)
8.2.1 Company Overview
8.2.2 Key Executives
8.2.3 Company Snapshot
8.2.4 Role of the Company in the Market
8.2.5 Sustainability and Social Responsibility
8.2.6 Operating Business Segments
8.2.7 Product Portfolio
8.2.8 Business Performance
8.2.9 Key Strategic Moves and Recent Developments
8.2.10 SWOT Analysis
8.3 TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL)
8.4 MYLAN N.V. (USA)
8.5 NOVARTIS AG (SWITZERLAND)
8.6 GSK (GLAXOSMITHKLINE) (UK)
8.7 BRISTOL-MYERS SQUIBB (USA)
8.8 ZYDUS CADILA (INDIA)
8.9 CIPLA LTD. (INDIA)
8.10 HIKMA
8.11 PHARMACEUTICALS (JORDAN)
8.12 SANDOZ (NOVARTIS) (SWITZERLAND)
8.13 LUPIN PHARMACEUTICALS (INDIA)
8.14 AMGEN (USA)
8.15 OTHER ACTIVE PLAYERS
Chapter 9: Global Hydroxychloroquine Market By Region
9.1 Overview
9.2. North America Hydroxychloroquine Market
9.2.1 Key Market Trends, Growth Factors and Opportunities
9.2.2 Top Key Companies
9.2.3 Historic and Forecasted Market Size by Segments
9.2.4 Historic and Forecasted Market Size By Application
9.2.4.1 Malaria
9.2.4.2 Rheumatoid Arthritis
9.2.4.3 Lupus
9.2.4.4 COVID-19
9.2.4.5 Others
9.2.5 Historic and Forecasted Market Size By Distribution Channel
9.2.5.1 Hospitals
9.2.5.2 Pharmacies
9.2.5.3 Online Pharmacies
9.2.6 Historic and Forecasted Market Size By Formulation
9.2.6.1 Tablets
9.2.6.2 Injections
9.2.7 Historic and Forecasted Market Size By End-User
9.2.7.1 Hospitals
9.2.7.2 Clinics
9.2.7.3 Homecare
9.2.8 Historic and Forecast Market Size by Country
9.2.8.1 US
9.2.8.2 Canada
9.2.8.3 Mexico
9.3. Eastern Europe Hydroxychloroquine Market
9.3.1 Key Market Trends, Growth Factors and Opportunities
9.3.2 Top Key Companies
9.3.3 Historic and Forecasted Market Size by Segments
9.3.4 Historic and Forecasted Market Size By Application
9.3.4.1 Malaria
9.3.4.2 Rheumatoid Arthritis
9.3.4.3 Lupus
9.3.4.4 COVID-19
9.3.4.5 Others
9.3.5 Historic and Forecasted Market Size By Distribution Channel
9.3.5.1 Hospitals
9.3.5.2 Pharmacies
9.3.5.3 Online Pharmacies
9.3.6 Historic and Forecasted Market Size By Formulation
9.3.6.1 Tablets
9.3.6.2 Injections
9.3.7 Historic and Forecasted Market Size By End-User
9.3.7.1 Hospitals
9.3.7.2 Clinics
9.3.7.3 Homecare
9.3.8 Historic and Forecast Market Size by Country
9.3.8.1 Russia
9.3.8.2 Bulgaria
9.3.8.3 The Czech Republic
9.3.8.4 Hungary
9.3.8.5 Poland
9.3.8.6 Romania
9.3.8.7 Rest of Eastern Europe
9.4. Western Europe Hydroxychloroquine Market
9.4.1 Key Market Trends, Growth Factors and Opportunities
9.4.2 Top Key Companies
9.4.3 Historic and Forecasted Market Size by Segments
9.4.4 Historic and Forecasted Market Size By Application
9.4.4.1 Malaria
9.4.4.2 Rheumatoid Arthritis
9.4.4.3 Lupus
9.4.4.4 COVID-19
9.4.4.5 Others
9.4.5 Historic and Forecasted Market Size By Distribution Channel
9.4.5.1 Hospitals
9.4.5.2 Pharmacies
9.4.5.3 Online Pharmacies
9.4.6 Historic and Forecasted Market Size By Formulation
9.4.6.1 Tablets
9.4.6.2 Injections
9.4.7 Historic and Forecasted Market Size By End-User
9.4.7.1 Hospitals
9.4.7.2 Clinics
9.4.7.3 Homecare
9.4.8 Historic and Forecast Market Size by Country
9.4.8.1 Germany
9.4.8.2 UK
9.4.8.3 France
9.4.8.4 The Netherlands
9.4.8.5 Italy
9.4.8.6 Spain
9.4.8.7 Rest of Western Europe
9.5. Asia Pacific Hydroxychloroquine Market
9.5.1 Key Market Trends, Growth Factors and Opportunities
9.5.2 Top Key Companies
9.5.3 Historic and Forecasted Market Size by Segments
9.5.4 Historic and Forecasted Market Size By Application
9.5.4.1 Malaria
9.5.4.2 Rheumatoid Arthritis
9.5.4.3 Lupus
9.5.4.4 COVID-19
9.5.4.5 Others
9.5.5 Historic and Forecasted Market Size By Distribution Channel
9.5.5.1 Hospitals
9.5.5.2 Pharmacies
9.5.5.3 Online Pharmacies
9.5.6 Historic and Forecasted Market Size By Formulation
9.5.6.1 Tablets
9.5.6.2 Injections
9.5.7 Historic and Forecasted Market Size By End-User
9.5.7.1 Hospitals
9.5.7.2 Clinics
9.5.7.3 Homecare
9.5.8 Historic and Forecast Market Size by Country
9.5.8.1 China
9.5.8.2 India
9.5.8.3 Japan
9.5.8.4 South Korea
9.5.8.5 Malaysia
9.5.8.6 Thailand
9.5.8.7 Vietnam
9.5.8.8 The Philippines
9.5.8.9 Australia
9.5.8.10 New Zealand
9.5.8.11 Rest of APAC
9.6. Middle East & Africa Hydroxychloroquine Market
9.6.1 Key Market Trends, Growth Factors and Opportunities
9.6.2 Top Key Companies
9.6.3 Historic and Forecasted Market Size by Segments
9.6.4 Historic and Forecasted Market Size By Application
9.6.4.1 Malaria
9.6.4.2 Rheumatoid Arthritis
9.6.4.3 Lupus
9.6.4.4 COVID-19
9.6.4.5 Others
9.6.5 Historic and Forecasted Market Size By Distribution Channel
9.6.5.1 Hospitals
9.6.5.2 Pharmacies
9.6.5.3 Online Pharmacies
9.6.6 Historic and Forecasted Market Size By Formulation
9.6.6.1 Tablets
9.6.6.2 Injections
9.6.7 Historic and Forecasted Market Size By End-User
9.6.7.1 Hospitals
9.6.7.2 Clinics
9.6.7.3 Homecare
9.6.8 Historic and Forecast Market Size by Country
9.6.8.1 Turkiye
9.6.8.2 Bahrain
9.6.8.3 Kuwait
9.6.8.4 Saudi Arabia
9.6.8.5 Qatar
9.6.8.6 UAE
9.6.8.7 Israel
9.6.8.8 South Africa
9.7. South America Hydroxychloroquine Market
9.7.1 Key Market Trends, Growth Factors and Opportunities
9.7.2 Top Key Companies
9.7.3 Historic and Forecasted Market Size by Segments
9.7.4 Historic and Forecasted Market Size By Application
9.7.4.1 Malaria
9.7.4.2 Rheumatoid Arthritis
9.7.4.3 Lupus
9.7.4.4 COVID-19
9.7.4.5 Others
9.7.5 Historic and Forecasted Market Size By Distribution Channel
9.7.5.1 Hospitals
9.7.5.2 Pharmacies
9.7.5.3 Online Pharmacies
9.7.6 Historic and Forecasted Market Size By Formulation
9.7.6.1 Tablets
9.7.6.2 Injections
9.7.7 Historic and Forecasted Market Size By End-User
9.7.7.1 Hospitals
9.7.7.2 Clinics
9.7.7.3 Homecare
9.7.8 Historic and Forecast Market Size by Country
9.7.8.1 Brazil
9.7.8.2 Argentina
9.7.8.3 Rest of SA
Chapter 10 Analyst Viewpoint and Conclusion
10.1 Recommendations and Concluding Analysis
10.2 Potential Market Strategies
Chapter 11 Research Methodology
11.1 Research Process
11.2 Primary Research
11.3 Secondary Research
|
Global Hydroxychloroquine Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 4.22 Billion |
|
Forecast Period 2024-32 CAGR: |
5.6% |
Market Size in 2032: |
USD 6.89 Billion |
|
Segments Covered: |
By Formulation |
|
|
|
By Application |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the Report: |
|
||
